Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy

Arch Ital Urol Androl. 2022 Dec 28;94(4):521-524. doi: 10.4081/aiua.2022.4.521.

Abstract

To the Editor, Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in elderly males. The current guidelines recommend the use of a 5-alpha reductase inhibitor (5ARI) to treat males with moderate-to-severe LUTS and an enlarged prostate. Combination therapy with an alpha blocker and a 5ARI has proven effective at ameliorating LUTS and reducing the total prostate volume (TPV) and the risk of the disease progression.

MeSH terms

  • 5-alpha Reductase Inhibitors / therapeutic use
  • Adrenergic alpha-Antagonists / therapeutic use
  • Aged
  • Drug Therapy, Combination
  • Dutasteride / therapeutic use
  • Humans
  • Lower Urinary Tract Symptoms* / drug therapy
  • Lower Urinary Tract Symptoms* / etiology
  • Male
  • Prostate
  • Prostatic Hyperplasia* / diagnosis
  • Prostatic Hyperplasia* / drug therapy

Substances

  • Dutasteride
  • 5-alpha Reductase Inhibitors
  • Adrenergic alpha-Antagonists